HLA-C and neoplasm: Unlike TILs and TCRs, which specifically recognize MHC-presented antigens, CARs do not depend on MHC expression, and even if MHC expression is down-regulated in tumor cells, CARs still efficiently recognize antigens and kill tumor cells (Cohen, 2018), which may be the greatest advantage of CAR-T over other modalities.